Revolution Medicines to Participate in November 2025 Investor Conferences

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD) announced that CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will participate in two investor conference fireside chats in November 2025.

Event details: Guggenheim Healthcare Innovation Conference fireside chat on Tuesday, November 11, 2025 at 9:00 a.m. ET, and Jefferies Global Healthcare Conference fireside chat on Tuesday, November 18, 2025 at 9:30 a.m. GMT. Live webcasts and archived replays will be available at the company investor events page, with replay access for at least 14 days.

REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in two upcoming investor conferences.

Details of the company’s participation are as follows:

• Guggenheim 2^nd Annual Healthcare Innovation Conference
  • Fireside Chat: Tuesday, November 11 at 9:00 a.m. ET

• Jefferies Global Healthcare Conference
  • Fireside Chat: Tuesday, November 18 at 9:30 a.m. GMT

To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

FAQ

When will Revolution Medicines (RVMD) present at the Guggenheim Healthcare Innovation Conference?

RVMD CEO Mark A. Goldsmith will appear on a fireside chat on Tuesday, November 11, 2025 at 9:00 a.m. ET.

What time is the Revolution Medicines (RVMD) fireside chat at the Jefferies Global Healthcare Conference?

The Jefferies fireside chat is scheduled for Tuesday, November 18, 2025 at 9:30 a.m. GMT.

How can investors listen to the Revolution Medicines (RVMD) conference webcasts?

Investors can access live webcasts and archived replays via the company investor events page at https://ir.revmed.com/events-and-presentations.

Will Revolution Medicines (RVMD) provide replays of the November 2025 presentations?

Yes. Replays will be available on the company website for at least 14 days after the live webcast.

Who is representing Revolution Medicines (RVMD) at the November 2025 investor conferences?

CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will represent the company at both events.